Second Sight Medical Products Stock Forecast, Price & News

Wall Street analysts have given Second Sight Medical Products a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Second Sight Medical Products wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Second Sight Medical Products saw a drop in short interest during the month of March. As of March 31st, there was short interest totaling 2,400,000 shares, a drop of 22.6% from the March 15th total of 3,100,000 shares. Based on an average trading volume of 23,710,000 shares, the short-interest ratio is presently 0.1 days. Approximately 38.2% of the company's shares are short sold.
View Second Sight Medical Products' Short Interest.

Second Sight Medical Products, Inc. (NASDAQ:EYES) posted its quarterly earnings results on Monday, June, 29th. The medical device company reported ($0.57) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.41) by $0.16.
View Second Sight Medical Products' earnings history.

Second Sight Medical Products' stock was trading at $3.53 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, EYES stock has increased by 133.4% and is now trading at $8.24.
View which stocks have been most impacted by COVID-19.

5 employees have rated Second Sight Medical Products CEO Will McGuire on Glassdoor.com. Will McGuire has an approval rating of 57% among Second Sight Medical Products' employees. This puts Will McGuire in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Second Sight Medical Products include Semler Scientific (SMLR), ViewRay (VRAY), Stereotaxis (STXS), Cutera (CUTR), Zynex (ZYXI), Edap Tms (EDAP), BioSig Technologies (BSGM), FONAR (FONR), IRIDEX (IRIX), Soleno Therapeutics (SLNO), ENDRA Life Sciences (NDRA), electroCore (ECOR), Electromed (ELMD), Helius Medical Technologies (HSDT) and Fc Global Realty (FCRE).
View all of EYES's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Second Sight Medical Products investors own include Zynerba Pharmaceuticals (ZYNE), Adaptimmune Therapeutics (ADAP), Cara Therapeutics (CARA), VBI Vaccines (VBIV), Shopify (SHOP), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), (CGC), Ekso Bionics (EKSO) and OPKO Health (OPK).

(EYES) raised $32 million in an IPO on Wednesday, November 19th 2014. The company issued 3,500,000 shares at a price of $9.00 per share. MDB Capital Group, LLC acted as the underwriter for the IPO.

Second Sight Medical Products trades on the NASDAQ under the ticker symbol "EYES."

Shares of EYES can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EYES stock can currently be purchased for approximately $8.24.

Second Sight Medical Products has a market capitalization of $191.58 million and generates $3.38 million in revenue each year. The medical device company earns $-33,590,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis.

Second Sight Medical Products employs 12 workers across the globe.

The official website for Second Sight Medical Products is www.secondsight.com.

Second Sight Medical Products is headquartered at 12744 SAN FERNANDO ROAD SUITE 400, SYLMAR CA, 91342.

Second Sight Medical Products' mailing address is 12744 SAN FERNANDO ROAD SUITE 400, SYLMAR CA, 91342. The medical device company can be reached via phone at 818-833-5000 or via email at [email protected]